Dihydrotachysterol
Chemical compound
- A11CC02 (WHO)
- (1S,3E,4S)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-Dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol
- 67-96-9
Y
- 5311071
- DB01070 Y
- 4470607 Y
- R5LM3H112R
- D00299 Y
- CHEBI:4591 Y
- DTXSID5022938
- Interactive image
- O[C@@H]3C/C(=C\C=C1/CCC[C@]2([C@H]1CC[C@@H]2[C@@H](/C=C/[C@H](C)C(C)C)C)C)[C@@H](C)CC3
InChI
- InChI=1S/C28H46O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-22,25-27,29H,7-8,11,14-18H2,1-6H3/b10-9+,23-12+,24-13+/t20-,21-,22+,25-,26+,27-,28+/m0/s1Y
- Key:ILYCWAKSDCYMBB-OPCMSESCSA-NY
Dihydrotachysterol (DHT) is a synthetic vitamin D analog activated in the liver that does not require renal hydroxylation like vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). DHT has a rapid onset of action (2 hours), a shorter half-life, and a greater effect on mineralization of bone salts than does vitamin D.[1]
References
- ^ Gagnon R, Ogden GW, Just G, Kaye M (April 1974). "Comparison of dihydrotachysterol and 5,6-trans vitamin D3 on intestinal calcium absorption in patients with chronic renal failure". Canadian Journal of Physiology and Pharmacology. 52 (2): 272–4. doi:10.1139/y74-037. PMID 4365509.
- v
- t
- e
- Adosterol
- Cholecalciferol/Ergocalciferols
- Cholesterol
- Dihydrotachysterol
- Fusidic acid
- Lanosterol
- Phytosterols
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
